Previous Close | 49.54 |
Open | 49.29 |
Bid | 49.28 x 1200 |
Ask | 0.00 x 800 |
Day's Range | 48.90 - 49.44 |
52 Week Range | 40.38 - 51.30 |
Volume | |
Avg. Volume | 725,218 |
Market Cap | 11.228B |
Beta (5Y Monthly) | 0.38 |
PE Ratio (TTM) | 24.41 |
EPS (TTM) | 2.02 |
Earnings Date | Feb 07, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 53.80 |
Subscribe to Yahoo Finance Plus to view Fair Value for QGEN
Genetic Technologies Limited (NASDAQ: GENE) agreed to form a strategic alliance with Qiagen NV (NYSE: QGEN) to establish and develop a 'Centre of Excellence facility in Australia. Qiagen will support the improvement of GTG capabilities through software, hardware, consumable and technical solutions. Genetic Technologies CEO Simon Morriss said it was an exciting opportunity for the company. "We are extremely excited to be forming this alliance with the regional subsidiary of such a prestigious glo
Qiagen (QGEN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Qiagen (QGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.